20/20 GeneSystems, Inc.
20/20 GeneSystems, headquartered in Rockville, Maryland (outside of Washington, D.C.), is a revenue stage diagnostics company that uses machine learning algorithms to greatly improve the accuracy of laboratory tests for the early detection of cancer and other diseases. In the most recent calendar year our revenues grew to over $2 million aided by several COVID-19 tests that we are successfully commercializing.
Our multi-cancer early detection blood test (www.OneTest.Ai) measures tumor antigens and uses a machine learning algorithm powered by outcome data from over 230,000 individuals tested in real-world screening settings. OneTest is a highly accessible and affordable pre-test that can be followed up with more expensive and specific circulating tumor DNA tests such as those being developed by Grail and Thrive Earlier Detection. (Those companies were recently acquired for $8 billion and $2 billion respectively.)
20/20’s institutional investors include Ping An, one of the largest digital health and insurance companies in China, and several well-regarded American funds. We are working to an initial public offering in 2021 and are now lining up IPO “crossover” investors.
Mr. Jonathan Cohen
CEORichard Brand
CFOJiming Zhou
COOable cerebral, llc
ACL is a bio-pharmaceutical and medical device company with patented (US & China) technologies and products.
We have achieved our first goal via BrainGlucoseTM by providing timed release of brain energy as circadian therapy to eliminate nightmares, night sweating, hallucinations, which have been saving lives and dignity of many early and mid-stage Alzheimer’s patients; and to help diabetics to avoid nocturnal hypoglycemia for better sleep and protection from seizures, coma or even death.
More excitingly, through communications with FDA and experts in biopharmaceutical fields, we are initiating for phase III clinical study inquiry for our delayed and sustained release of energy product as breakthrough new drug status for Alzheimer’s disease.
We are also looking for investment or partnership to advance our game changing technology product, a noninvasive medical device, AddMemTM, which will be also the world’s first ever product for memory consolidation and recovery.
ACL is also a licensed manufacturer for medical food in Pennsylvania.
Our product can be marketed in China through registration with Chinese FDA as “special medical formulated food”, or apply as a new drug.
Dr. jun xia
Co-Founder / PresidentAbpro
We have a very unique T-cell engager Bi-specific antibody platform.
Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.
We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.
We are looking for China partners to codevelop the Bi-specific antibodies.
We are also raising the capital to set up the CHina subsidiary.
You can add my wechat: elite8800
John Xu
SVPAbsenteeism. Presenteeism.
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Mr. Leo Petrilli
Addiction Recovery Coach AND MentorAbveris Inc.
Gary Ng
Director of MarketingAchelios Therapeutics
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Dr. Crist Frangakis
President & ceoAcon Pharmaceuticals Inc
We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.